Politics
What Does The Federal Government’s Registration Of 900+ Medical Cannabis Dispensaries Mean For Patients? (Op-Ed)
“For the first time, the federal government is recognizing and registering the medical cannabis dispensaries that patients fought to establish. This is a tremendous victory for patient access and an opportunity to build on 30 years of progress.”
By Steph Sherer, Americans for Safe Access
On Friday, the U.S. Department of Justice announced that the Drug Enforcement Administration (DEA) is moving forward with federal registrations for more than 900 state-licensed medical cannabis dispensaries across seven states.
This marks a major implementation milestone under the attorney general’s order establishing a federal regulatory pathway for qualifying state medical cannabis activities under Schedule III.
For medical cannabis patients, this is a historic achievement as we approach the 30th anniversary of California’s Proposition 215, the nation’s first statewide medical cannabis law. The federal government is now formally recognizing and registering the dispensaries that patients fought to establish, bringing decades of patient advocacy and state medical cannabis programs into a new era of federal recognition.
Here are 10 things patients, caregivers, healthcare professionals, cannabis providers and policymakers should know about this announcement.
1. This Is A Historic Victory For Medical Cannabis Patients.
For the first time, DEA is registering state-licensed medical cannabis dispensaries under a federal framework that recognizes qualifying medical cannabis activity.
Thirty years ago, patients turned to state governments to establish access to cannabis medicines because federal policy would not recognize their medical use. Today, the federal government is beginning to regulate those same state-established access systems.
This progress builds on decades of patient advocacy, state policy development and efforts to establish standards for safe medical cannabis access.
2. More Than 900 Dispensaries Are Included In The First Round Of Federal Registrations.
The initial registrations cover dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia.
The announcement’s scale is especially encouraging. Based on available state data, these seven states collectively have roughly 1,100 medical cannabis dispensing locations, although licensing structures and reporting methods differ. Florida alone has nearly 800 dispensing locations, and Mississippi has approximately 175 to 200 licensed or operating dispensaries.
We do not yet know how many dispensaries applied, how many applications remain pending or how federal registrations correspond to individual state locations. Nevertheless, the announcement suggests substantial participation in the new federal framework.
An important distinction is that six of the seven states have medical-only cannabis programs. Virginia permits adult-use possession but has not yet implemented adult-use retail sales. This means the initial registrations do not yet tell us how DEA will handle dispensaries in states with established dual medical and adult-use licensing systems.
These registrations do not represent 900 newly opened dispensaries. They represent federal recognition of qualifying dispensaries operating under state medical cannabis systems.
3. Qualifying Medical Cannabis Is Now Being Regulated Under Schedule III.
The attorney general’s order established Schedule III controls for certain qualifying medical cannabis products and activities, creating a federal pathway for state-licensed medical cannabis businesses to register with DEA.
This represents a major change from the federal framework that historically treated state medical cannabis activity as Schedule I activity.
However, the order does not move all cannabis into Schedule III. Cannabis activities outside its scope remain subject to Schedule I controls, and the broader federal rescheduling proceeding remains separate.
Federal registration also does not authorize adult-use cannabis sales.
4. State Medical Cannabis Programs Are Becoming Part Of The Federal Regulatory System.
One of the most significant aspects of this development is that federal regulators are building on existing state medical cannabis programs rather than requiring patients and states to abandon the systems they have established.
Dispensaries must meet federal registration requirements in addition to applicable state requirements, including DEA’s pre-registration investigation and federal security, inventory and recordkeeping controls.
Federal regulators are also reviewing applications from medical cannabis manufacturers and distributors, which are essential to maintaining the supply chains patients depend on.
The continued recognition of state medical cannabis systems provides an opportunity to strengthen oversight while preserving established patient access.
5. Patients Should Maintain Their Medical Cannabis Documentation And Enrollment.
The federal registration announcement does not eliminate state medical cannabis requirements or automatically enroll patients in a federal program.
Patients should continue following the requirements of their state’s medical cannabis program, including maintaining applicable patient identification cards, healthcare provider certifications and other documentation.
Patients who currently obtain their medicines through adult-use dispensaries should pay particular attention to whether their state offers a separate medical cannabis pathway.
Maintaining medical documentation may become increasingly important as states distinguish federally qualifying medical cannabis activity from adult-use activity.
6. Federal Recognition Strengthens Opportunities To Advance Patients’ Rights.
For decades, patients have faced discrimination involving employment, housing, healthcare and other essential services because they use cannabis medicines recommended by their healthcare providers.
The new federal framework creates opportunities to challenge outdated policies and seek clarification of federal patient protections. However, federal registration does not automatically guarantee workplace accommodations, hospital access, housing protections or other rights.
Americans for Safe Access has expanded its Patients’ Rights Campaign to the federal level to help patients understand changing laws, assert applicable protections, request individualized consideration, and document discrimination.
7. Important Barriers To Patient Access Remain.
Federal dispensary registration is a significant achievement, but it does not automatically establish a nationwide medical cannabis program.
Patients may still face different eligibility requirements, product availability, costs and legal protections depending on where they live.
The announcement does not automatically authorize interstate transportation of cannabis, require insurance coverage or resolve restrictions affecting patients in federal housing, workplaces or healthcare facilities.
These issues require additional federal guidance, state implementation, and, in some cases, congressional action.
8. The Next Challenge Is Implementing Federal Registration In States With Both Medical And Adult-Use Cannabis Programs.
Six of the seven states included in the initial announcement have medical-only cannabis programs. Virginia has legalized adult-use possession, but retail sales have not yet begun.
The next major test will be how federal registration works in states where medical and adult-use cannabis are regulated together or where patients rely on dispensaries holding both types of licenses. These states may need additional procedures to identify qualifying medical cannabis transactions, verify patient status and distinguish medical activity from adult-use activity.
DOJ and DEA cannot directly change state licensing laws, but they can provide federal guidance and work with state regulators to identify compliant pathways for existing medical cannabis operators. States may also need to modify their licensing systems or regulations to accommodate federal requirements.
ASA has already provided states with recommendations for preparing medical cannabis programs for federal regulation, preserving medical cannabis supply chains, supporting DEA registration and protecting patients during the transition.
9. Federal Registration Is Progress, But Congress Still Needs To Establish A National Medical Cannabis Program.
DEA registration creates an important regulatory pathway, but it does not resolve every issue involved in integrating medical cannabis into the U.S. healthcare system.
Americans for Safe Access has proposed the Medical Cannabis & Cannabinoid Act (MCCA) to build on this progress through a comprehensive national medical cannabis framework. The MCCA would establish a new Schedule VI for cannabis and cannabinoids and create an Office of Medical Cannabis and Cannabinoid Control within the Department of Health and Human Services.
This framework would address patient access, product safety, research, healthcare integration, and patient protections, building on lessons learned from state medical cannabis programs.
10. The Next Congress Will Play A Critical Role In What Happens Next.
With the midterm elections on Tuesday, DOJ’s announcement underscores the significance of federal medical cannabis policy for the next Congress.
Federal agencies have begun implementing a new regulatory framework, but Congress will have opportunities to address outstanding questions involving patient protections, national access, healthcare integration and oversight of federal implementation.
Through ASA’s Compassionate Candidate Campaign, candidates from every political party are invited to publicly commit to supporting comprehensive medical cannabis legislation and using congressional oversight to advance meaningful patient protections.
The actions of the next Congress will determine how the progress achieved through rescheduling and registration translates into long-term healthcare policy.
30 Years Of Patient Progress And A New Era Of Federal Recognition
For the first time, the federal government is recognizing and registering the medical cannabis dispensaries that patients fought to establish. This is a tremendous victory for patient access and an opportunity to build on 30 years of progress.
Today’s announcement marks a historic achievement in the effort to bring medical cannabis into federal policy. It demonstrates that a federal regulatory framework can build on the program’s patients, healthcare professionals and states have spent decades creating.
As we approach the 30th anniversary of California’s Proposition 215, there is reason for optimism about the future of medical cannabis in America. Federal recognition is advancing, new opportunities for patient protections are emerging and a foundation exists for building a comprehensive national medical cannabis program.
The next phase is about building on this progress, protecting the access patients have established and making the benefits of federal recognition available to more patients across the country.
Steph Sherer is the founder and executive director of Americans for Safe Access.
